Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expanding the rare disease medicines portfolio, focusing on supporting patients.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News